Wells Fargo & Company Has Lowered Expectations for argenex (NASDAQ:ARGX) Stock Price

argenex (NASDAQ:ARGX) had its target price dropped by equities research analysts at Wells Fargo & Company from $1,356.00 to $1,336.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 54.03% from the company’s current price.

A number of other brokerages have also weighed in on ARGX. Jefferies Financial Group reaffirmed a “buy” rating on shares of argenex in a report on Monday, September 14th. Guggenheim initiated coverage on shares of argenex in a research report on Tuesday, August 4th. They set a “buy” rating and a $1,185.00 target price on the stock. Oppenheimer lowered their price target on shares of argenex from $1,100.00 to $1,038.00 and set an “outperform” rating on the stock in a research note on Monday, October 12th. Robert W. Baird increased their price target on shares of argenex from $823.00 to $861.00 and gave the company a “neutral” rating in a report on Friday. Finally, Morgan Stanley increased their price target on shares of argenex from $1,230.00 to $1,250.00 and gave the company an “overweight” rating in a report on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $1,148.95.

argenex Stock Performance

ARGX traded down $8.42 during trading on Friday, reaching $867.34. The company’s stock had a trading volume of 57,760 shares, compared to its average volume of 351,519. The company’s fifty day moving average price is $956.17 and its 200-day moving average price is $885.45. argenex has a 52-week low of $661.85 and a 52-week high of $1,072.75. The company has a market capitalization of $54.55 billion, a price-to-earnings ratio of 33.32, a price-to-earnings-growth ratio of 0.82 and a beta of 0.44.

argenex (NASDAQ:ARGX) last issued its earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. The business had revenue of $1.75 billion during the quarter. argenex had a return on equity of 43.59% and a net margin of 32.19%. Equities analysts predict that argenex will post 28.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARGX. Whipplewood Advisors LLC acquired a new position in argenex during the first quarter worth about $28,000. Eastern Bank acquired a new position in argenex in the second quarter valued at $32,000. Axiom Investment Management LLC purchased a new position in shares of argenex during the 1st quarter worth about $50,000. WPG Advisers LLC boosted its holdings in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after purchasing an additional 13 shares during the last quarter. Finally, Mather Group LLC. raised its holdings in shares of argenex by 19.1% in the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after purchasing an additional 13 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported third-quarter revenue of approximately $1.75 billion, with product net sales up 54% year over year to $1.7 billion. Earnings of $7.80 per share exceeded the $7.44 consensus estimate, while operating profit reached $486 million, or a 28% margin. Argenx SE Stock Falls Despite $1.7 Billion Sales and Profit Growth
• Positive Sentiment: Jefferies said the recent weakness may create an attractive entry point and maintained a favorable view of argenx’s setup through year-end 2026. Jefferies Analyst Commentary
• Neutral Sentiment: Robert W. Baird raised its price target from $823 to $861 but retained a neutral rating, implying limited upside at the reported share price. Royal Bank of Canada separately cut its target, underscoring mixed analyst sentiment. Robert W. Baird Analyst Ratings RBC Price Target Update
• Negative Sentiment: A surprise testing setback in a VYVGART-related study for Sjögren’s syndrome raised concerns about the breadth and timing of argenx’s pipeline expansion. Because VYVGART is the company’s primary commercial growth driver, the news overshadowed the quarterly earnings beat and strong sales growth. Argenx Testing Setback

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.